Four IPOs priced this past week, led by three sizable biotechs. They were joined by 11 blank check listings. Coagulation disorder biotech Hemab Therapeutics (COAG) upsized and priced at the high end to raise $302 million at an $849 million market cap. Hemab...read more
Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, raised $255 million by offering 14.2 million shares at $18, the high end of the $16 to $18 range. The company offered 2.4 million more shares than anticipated....read more
Thirteen IPOs raised a combined $7.3 billion in April, joined by two direct listings. While surging volatility in March weighed on new issuance early on, activity ended in line with April’s 10-year historical average by deal count (15) but well above by...read more
Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $201 million by offering 11.8 million shares at a price range of $16 to $18....read more
US IPO Weekly Recap: Biotech, early-stage mining, and Bill Ackman close out the April IPO market
Four IPOs priced this past week, led by three sizable biotechs. They were joined by 11 blank check listings. Coagulation disorder biotech Hemab Therapeutics (COAG) upsized and priced at the high end to raise $302 million at an $849 million market cap. Hemab...read more
Neuropsychiatric therapeutics Seaport Therapeutics prices upsized IPO at $18, the high end of the range
Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, raised $255 million by offering 14.2 million shares at $18, the high end of the $16 to $18 range. The company offered 2.4 million more shares than anticipated....read more
Renaissance Capital’s April IPO Market Update
Thirteen IPOs raised a combined $7.3 billion in April, joined by two direct listings. While surging volatility in March weighed on new issuance early on, activity ended in line with April’s 10-year historical average by deal count (15) but well above by...read more
Neuropsychiatric therapeutics Seaport Therapeutics sets terms for $201 million IPO, pricing this week
Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $201 million by offering 11.8 million shares at a price range of $16 to $18....read more